Randomized phase three open-label trial with advanced NSCLC patients with EGFR mutation. The study added carboplatin and pemetrexed (CP) chemotherapy to G versus G alone to evaluate for improved outcomes. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.